BCS Bioceramic Sealer

K262478 · BCS Device Pte., Ltd. · KIF · Oct 16, 2026 · Dental

Device Facts

Record IDK262478
Device NameBCS Bioceramic Sealer
ApplicantBCS Device Pte., Ltd.
Product CodeKIF · Dental
Decision DateOct 16, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 872.3820
Device ClassClass 2
AttributesTherapeutic

Indications for Use

Permanent obturation of the root canal following vital pulp-extirpation Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings.

Device Story

BCS Bioceramic Sealer is a ready-to-use, fast-setting, white hydraulic premixed bioceramic paste; supplied in a preloaded syringe. Used by dentists for permanent root canal obturation. Material is an insoluble, radiopaque, aluminum-free calcium silicate composition; requires presence of water to set and harden. Does not shrink during setting. Benefits include effective sealing of root canal systems following pulp removal or treatment of necrotic pulp. Operates as a physical barrier within the canal.

Clinical Evidence

Bench testing only. Performance evaluated per ISO 6876 standards for endodontic sealing materials. Results demonstrate the device is safe, effective, and performs as well as or better than the predicate iRoot SP.

Technological Characteristics

Ready-to-use hydraulic premixed bioceramic paste; calcium silicate-based; aluminum-free; radiopaque. Packaged in preloaded syringe. Sets/hardens in presence of water. Non-shrinking. Tested per ISO 6876.

Indications for Use

Indicated for permanent root canal obturation in adolescents and adults following vital pulp-extirpation or removal of infected/necrotic pulp with intracanal dressings.

Regulatory Classification

Identification

A root canal filling resin is a device composed of material, such as methylmethacrylate, intended for use during endodontic therapy to fill the root canal of a tooth.

Predicate Devices

Submission Summary (Full Text)

{1} **FDA U.S. FOOD & DRUG** ADMINISTRATION October 16, 2026 BCS Device Pte., Ltd. Yongze Lyu Director 16 Kallang Pl. #03-31 Singapore, 339156 SINGAPORE Re: K262478 Trade/Device Name: BCS Bioceramic Sealer Regulation Number: 21 CFR 872.3820 Regulation Name: Root Canal Filling Resin Regulatory Class: Class II Product Code: KIF Dated: July 17, 2026 Received: July 20, 2026 Dear Yongze Lyu: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {2} K262478 - Yongze Lyu Page 2 Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the {3} K262478 - Yongze Lyu Page 3 Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, # MICHAEL E. ADJODHA -S Michael E. Adjodha, MChE, RAC, CQIA Assistant Director DHT1B: Division of Dental and ENT Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {4} # Indications for Use | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | | K262478 | ? | | --- | --- | --- | --- | | Please provide the device trade name(s). | | | ? | | BCS Bioceramic Sealer | | | | | Please provide your Indications for Use below. | | | ? | | • Permanent obturation of the root canal following vital pulp-extirpation • Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings. | | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | | ? | | Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☑ Adolescents (12 years old to < 22 years old) ☑ Adults (22 years old and greater) | | ? | {5} 510(k) #: K262478 # 510(k) Summary Prepared on: 2026-07-17 Contact Details 21 CFR 807.92(a)(1) | Applicant Name | BCS Device Pte. Ltd | | --- | --- | | Applicant Address | 16 Kallang PL #03-31 Singapore 339156 Singapore | | Applicant Contact Telephone | 8438 3109 | | Applicant Contact | Mr. Yongze Lyu | | Applicant Contact Email | xavierlyu2000@gmail.com | Device Name 21 CFR 807.92(a)(2) | Device Trade Name | BCS Bioceramic Sealer | | --- | --- | | Common Name | Root canal filling resin | | Classification Name | Resin, Root Canal Filling | | Regulation Number | 872.3820 | | Product Code(s) | KIF | Legally Marketed Predicate Devices 21 CFR 807.92(a)(3) | Predicate # | Predicate Trade Name (Primary Predicate is listed first) | Product Code | | --- | --- | --- | | K080917 | iRoot SP | KIF | | K212983 | Injectable Root Canal Bioceramic Sealer | KIF | | K102867 | iRoot FS | KIF | | K063422 | Bioaggregate | KIF | | K992727 | THE BI-DIRECTIONAL SPIRAL & EPOXY ROOT CANAL CEMENT SYSTEM | KIF | | K190537 | BIO-C Sealer Ion+ | KIF | ## Device Description Summary 21 CFR 807.92(a)(4) BCS Bioceramic Sealer is a convenient ready-to-use fast setting white hydraulic premixed bioceramic paste. Which is developed for Permanent obturation of the root canal following vital pulp-extirpation and Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings. The aforementioned product is an insoluble, radiopaque and aluminum-free material based on a calcium silicate composition, which requires the presence of water to set and harden. The products do not shrink during setting and demonstrate excellent physical properties. BCS Bioceramic Sealer is packaged in a preloaded syringe. ## Intended Use/Indications for Use 21 CFR 807.92(a)(5) - Permanent obturation of the root canal following vital pulp-extirpation - Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings. {6} ## Indications for Use Comparison 21 CFR 807.92(a)(5) The Indications for use of BCS Bioceramic Sealer is the same as the predicate device iRoot SP. ## Technological Comparison 21 CFR 807.92(a)(6) BCS Bioceramic Sealer has equivalent characteristics to iRoot SP, they are designed to for equivalent purpose, use similar materials and operate under the equivalent principles. The differences in chemical composition can have their safety and effectiveness shown through the other predicate devices included above. ## Non-Clinical and/or Clinical Tests Summary & Conclusions 21 CFR 807.92(b) Nonclinical bench performance testing was submitted to support the determination of substantial equivalence for the subject root canal sealer. The testing was selected to evaluate the key physical and performance characteristics of an endodontic sealing material and was based on test methods derived from ISO 6876: From the bench tests it can be concluded that we have satisfied the conditions set forth by ISO 6876. As such, based on the results of the tests, it can be concluded that BCS Bioceramic Sealer is safe, effective and can perform as well as or better then the legally marketed device such as its predicate device of iRoot SP.
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...